Arthrosi Therapeutics is a clinical-stage biotech company focused on the development of therapy for gout and chronic kidney disease. The company is self-described as working to create a people-centered environment.

Arthrosi Therapeutics, Inc.

Viva BioInnovator operates as the investment division of Viva Biotech Holdings, focusing on identifying and supporting early-stage biotech companies through investment and incubation.

Viva BioInnovator

Arthrosi Therapeutics, Inc. | 596 followers on LinkedIn. Arthrosi is a clinical-stage biotech company focused on developing game-changing therapy for gout and tophaceous gout. | Arthrosi Therapeutics is a leading clinical-stage biotech company dedicated to advancing therapies for gout disease. Our proprietary oral drug candidate, AR882 which is currently in clinical Phase 3, has demonstrated unprecedented sustained urate lowering in gout patients and reduction of tophi, showing exceptional potential to treat millions of patients suffering from gout and tophaceous gout. At Arthrosi Therapeutics, we are committed to transforming the treatment landscape and improving the lives of patients worldwide.

Sr. Director, Clinical Operations at Arthrosi Therapeutics

Liz Polvent

Bioanalytical Scientist

Andrea Clouser Roche

Founder, COO at Arthrosi Therapeutics

Shunqi Yan (颜顺启), Ph.D.

Co-Founder & CEO, Arthrosi Therapeutics, Inc.

Litain Yeh

We’ve just updated our page. Visit us to see the latest updates.

Metric
Company Name	Arthrosi Therapeutics, Inc.	Viva BioInnovator
Symbol
MSH ID	COM:ARTHROSI	COM:VIVABIOINNOVATOR
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Financial Services & Finance
Industry	Biotechnology	Biotechnology
Country	US	HK
Stage	Venture Round
Employee Count
Website	arthrosi.com	vivabioinnovator.com
LinkedIn	arthrosi-therapeutics-inc	viva-bioinnovator
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		176
Web Traffic Growth		-0.72
Valuation
Raised Capital	7M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ARTH

COM:ARTHROSI

Arthrosi Therapeutics, Inc.

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue